Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue and Competitors
Estimated Revenue & Valuation
- Tonix Pharmaceuticals Holding Corp. (TNXP)'s estimated annual revenue is currently $26.5M per year.
- Tonix Pharmaceuticals Holding Corp. (TNXP)'s estimated revenue per employee is $201,000
Employee Data
- Tonix Pharmaceuticals Holding Corp. (TNXP) has 132 Employees.
- Tonix Pharmaceuticals Holding Corp. (TNXP) grew their employee count by 9% last year.
Tonix Pharmaceuticals Holding Corp. (TNXP)'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP, Medical | Reveal Email/Phone |
3 | EVP, Strategic Development | Reveal Email/Phone |
4 | Head Talent Acquisition | Reveal Email/Phone |
5 | EVP Product Development | Reveal Email/Phone |
6 | EVP, Medical | Reveal Email/Phone |
7 | EVP, Infectious Disease Research and Development | Reveal Email/Phone |
8 | EVP, Research | Reveal Email/Phone |
9 | EVP, Experimental Chemistry | Reveal Email/Phone |
10 | VP Sales and Marketing (Migraine) | Reveal Email/Phone |
Tonix Pharmaceuticals Holding Corp. (TNXP) Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Tonix Pharmaceuticals Holding Corp. (TNXP)?
Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine. Further information about Tonix can be found at www.tonixpharma.com.
keywords:N/A
N/A
Total Funding
132
Number of Employees
$26.5M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tonix Pharmaceuticals Holding Corp. (TNXP) News
CHATHAM, N.J., April 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical...
They set a sell rating on the stock. Several institutional investors have recently bought and sold shares of TNXP. Royal Bank of Canada...
... of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased by over 3% pre-market today. Investors are responding positively to Tonix...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29M | 132 | -23% | $23.4M |
#2 | $27.1M | 132 | 6% | N/A |
#3 | $32.1M | 132 | 19% | N/A |
#4 | $17.2M | 132 | -7% | $436M |
#5 | $27.7M | 132 | -3% | N/A |